AGEN
Price
$2.71
Change
-$0.24 (-8.14%)
Updated
Dec 18, 04:59 PM (EDT)
HMTXF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Dec 17 closing price
Ad is loading...

AGEN vs HMTXF

Header iconAGEN vs HMTXF Comparison
Open Charts AGEN vs HMTXFBanner chart's image
Agenus
Price$2.71
Change-$0.24 (-8.14%)
Volume$1.74K
CapitalizationN/A
Hemostemix
Price$0.05
Change-$0.00 (-0.00%)
Volume$10.08K
CapitalizationN/A
AGEN vs HMTXF Comparison Chart
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. HMTXF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Hold and HMTXF is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (AGEN: $2.71 vs. HMTXF: $0.05)
Brand notoriety: AGEN and HMTXF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 125% vs. HMTXF: 59%
Market capitalization -- AGEN: $69.77M vs. HMTXF: $9.34M
AGEN [@Biotechnology] is valued at $69.77M. HMTXF’s [@Biotechnology] market capitalization is $9.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileHMTXF’s FA Score has 1 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • HMTXF’s FA Score: 1 green, 4 red.
According to our system of comparison, HMTXF is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while HMTXF’s TA Score has 3 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 4 bearish.
  • HMTXF’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than HMTXF.

Price Growth

AGEN (@Biotechnology) experienced а -16.97% price change this week, while HMTXF (@Biotechnology) price change was +6.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.11%. For the same industry, the average monthly price growth was -2.34%, and the average quarterly price growth was +0.25%.

Reported Earning Dates

AGEN is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-7.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGEN($69.8M) has a higher market cap than HMTXF($9.34M). HMTXF YTD gains are higher at: -5.570 vs. AGEN (-82.154).
AGENHMTXFAGEN / HMTXF
Capitalization69.8M9.34M748%
EBITDA-77.64MN/A-
Gain YTD-82.154-5.5701,475%
P/E Ratio0.46N/A-
Revenue160MN/A-
Total Cash44.8MN/A-
Total Debt78.4MN/A-
FUNDAMENTALS RATINGS
AGEN vs HMTXF: Fundamental Ratings
AGEN
HMTXF
OUTLOOK RATING
1..100
6382
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
95100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HMTXF's Valuation (3) in the null industry is significantly better than the same rating for AGEN (96) in the Biotechnology industry. This means that HMTXF’s stock grew significantly faster than AGEN’s over the last 12 months.

HMTXF's Profit vs Risk Rating (100) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

HMTXF's SMR Rating (100) in the null industry is in the same range as AGEN (100) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

HMTXF's Price Growth Rating (65) in the null industry is in the same range as AGEN (65) in the Biotechnology industry. This means that HMTXF’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as HMTXF (100) in the null industry. This means that AGEN’s stock grew similarly to HMTXF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENHMTXF
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 24 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
N/A
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HMTXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
T22.83-0.01
-0.04%
AT&T
DTC1.12-0.01
-0.88%
Solo Brands
SKE9.39-0.09
-0.95%
Skeena Resources Limited
STAG35.38-0.43
-1.20%
Stag Industrial
WSBC34.53-0.77
-2.18%
WesBanco

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been closely correlated with SNPX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if AGEN jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
+4.42%
SNPX - AGEN
91%
Closely correlated
-1.99%
ALLR - AGEN
87%
Closely correlated
+15.18%
NRXP - AGEN
83%
Closely correlated
+36.67%
PALI - AGEN
81%
Closely correlated
+3.26%
AXON - AGEN
42%
Loosely correlated
-2.09%
More

HMTXF and

Correlation & Price change

A.I.dvisor tells us that HMTXF and DMAC have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HMTXF and DMAC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HMTXF
1D Price
Change %
HMTXF100%
-0.23%
DMAC - HMTXF
22%
Poorly correlated
-2.07%
BIVI - HMTXF
21%
Poorly correlated
-1.97%
AGEN - HMTXF
21%
Poorly correlated
+4.42%
DVHGF - HMTXF
21%
Poorly correlated
N/A
FDMT - HMTXF
12%
Poorly correlated
-2.47%
More